Across TCGA pan-cancer cohorts, PEX7 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PEX7 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PEX7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PEX7 expression acts as an unfavorable survival marker.
BRCA and COAD are the cancer types where PEX7 Mutation most reproducibly stratifies survival.